Ilex Medical ILX.TA · ILA

Its shares trade on Tel Aviv under the ticker ILX.TA. It has been listed since 1 January 1995. In the fiscal year to 31 December 2024, it reported revenue of ILS 920.4m and net income of ILS 39.0m. At that date it held total assets of ILS 994.1m and shareholders' equity of ILS 646.5m.

Ilex Medical Ltd. engages in medical diagnostics field. The company is a supplier of in vitro diagnostic equipment and laboratory management software. The firm offers cutting-edge diagnostic equipment and reagent systems; nucleic acid testing (NAT) blood screening solutions; products for cancer screening, retro virus load, TB, and STDs, and other infectious diseases; laboratory information systems (LIS); and blood sugar monitoring products. Among the Company’s subsidiaries and affiliates are Ilex South Africa, Orsyx-LIS, Ilex BioTech Ltd and Medtechnica Ltd.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Tamar GaliliChief Executive Officer, since 2006ILS 352,000
• Mr. Netanel AquaFinance Director
• Mr. Claude BenshaulChief Operating Officer, since 1993ILS 631,000
• Ms. Hilla Nissim-GabbayVice President - Finance
• Ms. Iris PerelmuterVice President of Sales and Marketing
• Mr. Ziv DahariVice President - Business Development
• Ms. Andrea Sitt-LevyGeneral Counsel, Secretary
• Ms. Lucien BenshaulDirector, since 1994
• Dr. Moshe BenshaulDirector, since 1990ILS 6.1m
• Ms. Lily AyalonExternal Director
• Ms. Hava ShechterIndependent Director
• Dr. Roberto Nathanson GoldstromExternal Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.